Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen

DB15517ApprovedWithdrawnVaccines

Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen is a recombinant hemagglutinin used in seasonal influenza vaccines. A seasonally-specific component of the influenza vaccine.

First approval: United States, 2019

Resolves to

Compound

UNIIDC4ELG1BFZ

Clinical / RWD

RxNorm2177290

What you can answer from here — as of September 01, 2026

7Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

7Marketed productsAcross 5 countries and 5 labellers

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account